Asgard Reprograms Tumors to Build Immune Niches
A study in Immunity reports the induction of immunogenic tertiary lymphoid structures across seven tumor types in mouse models.
Updated on Nov. 4, 2026 in Cancer
Asgard Therapeutics, a privately held biotech company, announced a study published in the journal Immunity showing its cell reprogramming platform induced immunogenic tertiary lymphoid structures across murine models of seven tumor types. The company also plans to present new AT-108 biomarker data at the SITC 2026 annual meeting.
Why it matters
Previous approaches have struggled to reliably induce these lymphoid structures across diverse tumor microenvironments, so a consistent method across several cancers is a notable step. The study is a collaboration between Asgard, Lund University, Shanghai Cancer Centre and the University of Coimbra.
The findings come from murine models of melanoma, colon, bladder, breast, lung, pancreatic and glioblastoma tumors, with 100% tumor regressions reported in colorectal and breast cancer models. Whether these preclinical results will hold in human patients remains unestablished.
The players
Asgard Therapeutics
A privately held biotech company based in Lund, Sweden, developing a cell reprogramming platform aimed at turning tumors into immune-activating environments.
Lund University
A Swedish public research university and a collaborating institution on the Immunity study.
Shanghai Cancer Centre
A cancer research and treatment center in Shanghai, China, that collaborated on the Immunity study.
University of Coimbra
A Portuguese public university and a collaborating institution on the Immunity study.
The details
Asgard's proprietary in vivo platform reprograms tumor cells into cDC1-like cells directly within tumors, inducing immunogenic tertiary lymphoid structures. AT-108 also produced dose-dependent immune remodeling and measurable changes in circulating immune cells after intratumoral administration.
Timeline
Nov. 4, 2026: Asgard announces the Immunity publication and its SITC data plans.
Nov. 4-8, 2026: SITC 41st Annual Meeting takes place in Phoenix, Arizona.
Nov. 6, 2026: AT-108 biomarker poster presentation at SITC (Abstract Number 1055).
2027: Planned advancement of AT-108 toward clinical trials.
Big Picture
Research on tertiary lymphoid structures has linked them to better immune responses in some cancers, and this study extends that line of work by inducing them across seven tumor types in mice. Whether such structures can be reliably created in human tumors is the central question the field has yet to answer.
Results from mouse models do not yet change how cancer is treated, and patients should not expect new therapies from this work in the near term. Any eventual clinical use would depend on human trials that have not yet been reported.
The takeaway
Results in mice are an early signal rather than proof of treatment, so readers should treat claims of cured cancers in animal studies with caution. Tracking whether such findings reach human trials is the best way to judge their real-world promise.
What happens next
Asgard will present AT-108 biomarker data at SITC 2026 in Phoenix, Arizona, with a poster presentation on Nov. 6, 2026, and the company aims to advance AT-108 toward the clinic in 2027.
Further reading
Explore more research in our Cancer section for context on immunotherapy approaches.
More information
Read the Immunity journal study on tertiary lymphoid structures for the full methods and results.
Source note: This article includes information reported by The Manila times.
